美食品加工巨擘嘉吉4月进入人造肉市场
《路透》报道,美国跨国食品加工巨擘嘉吉(Cargill)将於4月推出植物制汉堡扒及人造肉产品,挑战Beyond Meat及Impossible Foods等人造肉初创及其他同业。
美国泰臣食品(Tyson Foods)及万洲(00288.HK)旗下史密斯菲尔德(Smithfield)亦已出售植物制造的人造肉产品。
嘉吉将提供大豆蛋白或豌豆蛋白制造的汉堡扒与粉末产品,可用作制造墨西哥卷饼、意大利粉酱汁及其他菜肴。Beyond Meat及Impossible Foods的人造肉材料分别为豌豆蛋白及大豆蛋白。
市场对肉类替代品需求急升,民众增加食用植物制造蛋白,基於健康及动物福利忧虑,以至禽蓄业对环境的破坏。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.